The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer
Open accessAbstract
Significance: Cancer immune evasion is well described. In some cases, this may be overcome by enhancing T-cell responses. We show that despite the presence of antitumor T cells, immunotherapeutic antibodies are ineffective in a murine pancreatic cancer model recapitulating the human disease. Removing the carcinoma-associated fibroblast (CAF) expressing fibroblast activation protein (FAP) from tumors permitted immune control of tumor growth and uncovered the efficacy of these immunotherapeutic antibodies. FAP + CAFs are the only tumoral source of chemokine (C-X-C motif) ligand 12 (CXCL12), and administering AMD3100, an inhibitor of chemokine (C-X-C motif) receptor 4, a CXCL12 receptor, also revealed the antitumor effects of an immunotherapeutic antibody and greatly diminished cancer cells. These findings may have wide clinical relevance because FAP + cells are found in almost all human adenocarcinomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“targeting CXCL12 signalling could be considered to be targeting CAFs as they are the major source of the chemokine in many tumours121.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [121]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“most studies have suggested an immunosuppressive role of CAFs121”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [121]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Interference with the action of CXCL12 produced by CAFs promotes T cell-mediated tumour control16,121,122”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [121]
In the citing paper
“the transcriptional profiles of apCAFs overlap with mesothelial cells150, and based on lineage tracing studies in mice have been postulated to derive from a mesothelial origin145”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [150]
In the citing paper
“They can further differentiate into myofibroblasts that express α-smooth muscle actin232.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [232]
In the citing paper
“fibroblast activation protein (FAP)+ CAFs inhibited anti-tumor function of T cells in gastric cancer and pancreatic cancer and targeting these FAP+ subtypes enhanced tumor response to ICB (Feig et al., 2013).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Feig et al., 2013
In the citing paper
“Moreover, CAF depletion using diphtheria toxin‐based immunotherapy reduced cancer growth by increasing CD8+ Teff‐cell infiltration to the TME [102].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [102]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., DAUD, A. I., Hodi, F. S., Hwu, W., Kefford, R. F., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,427
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Cited by
Sorted by citations
Items 801–900 of 1,000
Immunotherapies in rare cancers
Vivekanandhan, S., Bahr, D. A., Kothari, A., Ashary, M. A., Baksh, M., & Gabriel, E. M. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01720-2 · Cited by 43
Pancreatic cancer: Update on immunotherapies and algenpantucel-L
McCormick, K. A., Coveler, A. L., Rossi, G. R., Vahanian, N. N., Link, C., & Chiorean, E. G. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1093264 · Cited by 42
The Potential Regulatory Roles of Circular RNAs in Tumor Immunology and Immunotherapy
Fang, Z., Jiang, C., & Li, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.617583 · Cited by 42
Su, F., Daquinag, A. C., Ahn, S., Saha, A., Dai, Y., Zhao, Z., DiGiovanni, J., & Kolonin, M. G. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00160-9 · Cited by 43
The tumour immune microenvironment in oesophageal cancer
Davern, M., Donlon, N. E., Power, R. F., Hayes, C., King, R., Dunne, M. R., & Reynolds, J. V. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01331-y · Cited by 45
A Tumor‐Penetrating Nanomedicine Improves the Chemoimmunotherapy of Pancreatic Cancer
Tong, Q., Miao, W., Huang, H., Luo, J., Liu, R., Huang, Y., Zhao, D., Shen, S., Du, J., & Wang, J. (2021) · Small · doi:10.1002/smll.202101208 · Cited by 42
Functions of the CXC ligand family in the pancreatic tumor microenvironment
Lee, N., Nikfarjam, M., & He, H. Z. (2018) · Pancreatology · doi:10.1016/j.pan.2018.07.011 · Cited by 42
Gong, J., Hendifar, A. E., Tuli, R., Chuang, J., Cho, M. T., Chung, V. M., Li, D., & Salgia, R. (2018) · Clinical and Translational Medicine · doi:10.1186/s40169-018-0210-9 · Cited by 41
Mundry, C. S., Eberle, K. C., Singh, P. K., Hollingsworth, M. A., & Mehla, K. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188387 · Cited by 41
Nano drug delivery system reconstruct tumour vasculature for the tumour vascular normalisation
Liang, Q., Zhou, L., Li, Y., Liu, J., & Liu, Y. (2021) · Journal of drug targeting · doi:10.1080/1061186x.2021.1927056 · Cited by 43
Koustas, E., Trifylli, E.-M., Sarantis, P., Papadopoulos, N., Karapedi, E., Aloizos, G., Damaskos, C., Garmpis, N., Garmpi, A., Papavassiliou, K. A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126664 · Cited by 43
Deciphering Tumor Niches: Lessons From Solid and Hematological Malignancies
Mancini, S. J. C., Balabanian, K., Corre, I., Gavard, J., Lazennec, G., Bousse‐Kerdilès, M. L., Louache, F., Maguer‐Satta, V., Mazure, N. M., Mechta‐Grigoriou, F., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.766275 · Cited by 43
Immunomodulatory effect of locoregional therapy in the tumor microenvironment
Xie, L., & Meng, Z. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.01.017 · Cited by 41
Dual IL-6 and CTLA-4 blockade regresses pancreatic tumors in a T cell– and CXCR3-dependent manner
Ware, M. B., Phillips, M., McQuinn, C. W., Zaidi, M. Y., Knochelmann, H. M., Greene, E. R., Robinson, B. S., Herting, C. J., Mace, T. A., Chen, Z., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.155006 · Cited by 42
A Quick Guide to CAF Subtypes in Pancreatic Cancer
Brichkina, A. I., Polo, P., Sharma, S. D., Visestamkul, N., & Lauth, M. (2023) · Cancers · doi:10.3390/cancers15092614 · Cited by 45
Zhang, Y., Han, X., Wang, K., Liu, D., Ding, X., Hu, Z., & Wang, J. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s418100 · Cited by 40
Magagna, I., Gourdin, N., Kieffer, Y., Licaj, M., Mhaidly, R., André, P., Morel, A., Vincent‐Salomon, A., Paturel, C., & Mechta‐Grigoriou, F. (2021) · Cancers · doi:10.3390/cancers13235878 · Cited by 40
Fibrous stroma: Driver and passenger in cancer development
Sharma, V., Letson, J., & Furuta, S. (2022) · Science Signaling · doi:10.1126/scisignal.abg3449 · Cited by 38
Cancer-Associated Fibroblasts: Lessons from Pancreatic Cancer
Sherman, M. H., & di Magliano, M. P. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061421-035400 · Cited by 39
Concise Review: Stem Cells in Pancreatic Cancer: From Concept to Translation
Raj, D., Aicher, A., & Heeschen, C. (2015) · Stem Cells · doi:10.1002/stem.2114 · Cited by 41
Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer
Bauer, C. A., Kühnemuth, B., Duewell, P., Ormanns, S., Gress, T. M., & Schnurr, M. M. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.02.057 · Cited by 41
Izar, B., Joyce, C. E., Goff, S. L., Cho, N. L., Shah, P., Sharma, G., Li, J., Ibrahim, N., Gold, J. S., Hodi, F. S., et al. (2016) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12513 · Cited by 39
Metabolic plasticity in heterogeneous pancreatic ductal adenocarcinoma
Liang, C., Qin, Y., Zhang, B., Ji, S., Shi, S., Xu, W., Liu, J., Xiang, J., Liang, D., Hu, Q., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.09.001 · Cited by 39
Ridinger-Saison, M., DelGiorno, K. E., Zhang, T., Kraus, A., French, R. P., Jaquish, D., Tsui, C., Erikson, G. A., Spike, B. T., Shokhirev, M. N., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0189051 · Cited by 40
CXCL12 and Its Isoforms: Different Roles in Pancreatic Cancer?
Righetti, A., Giulietti, M., Šabanović, B., Occhipinti, G., Principato, G., & Piva, F. (2019) · Journal of Oncology · doi:10.1155/2019/9681698 · Cited by 39
Alame, M., Cornillot, E., Cacheux, V., Tosato, G., Four, M., Oliveira, L. D., Gofflot, S., Delvenne, P., Turtoi, E., Cabello‐Aguilar, S., et al. (2020) · Theranostics · doi:10.7150/thno.42986 · Cited by 39
He, M., Henderson, M., Muth, S., Murphy, A., & Zheng, L. (2020) · Annals of Pancreatic Cancer · doi:10.21037/apc.2020.03.03 · Cited by 36
Hot and Cold Tumors: Is Endoglin (CD105) a Potential Target for Vessel Normalization?
Ollauri-Ibáñez, C., Ayuso-Íñigo, B., & Pericacho, M. (2021) · Cancers · doi:10.3390/cancers13071552 · Cited by 40
Addressing the obstacles of CAR T cell migration in solid tumors: wishing a heavy traffic
Kozani, P. S., Kozani, P. S., & Rahbarizadeh, F. (2021) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2021.1988509 · Cited by 42
Senescence of Tumor Cells in Anticancer Therapy—Beneficial and Detrimental Effects
Piskorz, W. M., & Cechowska‐Pasko, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911082 · Cited by 39
Runciman, D. (2011) · London review of books · Cited by 41
Meng, Q., Luo, X., Chen, J., Wang, D., Chen, E., Zhang, W., Zhang, G., Zhou, W., Xu, J., & Song, Z. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188443 · Cited by 38
Comprehensive analysis of the expression and prognostic value of CXC chemokines in colorectal cancer
Li, Y., Yang, X., Xu, C., Sun, J., Fang, Z., Pan, H., & Han, W. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107077 · Cited by 38
Modeling Pancreatic Cancer with Patient-Derived Organoids Integrating Cancer-Associated Fibroblasts
Go, Y.-H., Choi, W. H., Bae, W. J., Jung, S., Cho, C., Lee, S. A., Park, J. S., Ahn, J. M., Kim, S. W., Lee, K. J., et al. (2022) · Cancers · doi:10.3390/cancers14092077 · Cited by 39
Dual Role of Fibroblasts Educated by Tumour in Cancer Behavior and Therapeutic Perspectives
Toledo, B., Picon‐Ruiz, M., Marchal, J. A., & Perán, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415576 · Cited by 41
Bifunctional small molecules targeting PD-L1/CXCL12 as dual immunotherapy for cancer treatment
Cheng, B., Wang, W., Liu, T., Cao, H., Pan, W., Xiao, Y., Liu, S., & Chen, J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01292-5 · Cited by 38
Epigenetic regulation and therapeutic targets in the tumor microenvironment
Xie, Z., Zhou, Z., Yang, S., Zhang, S., & Shao, B. (2023) · Molecular Biomedicine · doi:10.1186/s43556-023-00126-2 · Cited by 38
Huang, J., Tsang, W. Y., Li, Z., & Guan, X. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.07.001 · Cited by 42
Yonemura, A., Semba, T., Zhang, J., Fan, Y., Yasuda‐Yoshihara, N., Wang, H., Uchihara, T., Yasuda, T., Nishimura, A., Fu, L., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2023.113613 · Cited by 38
Milosevic, V., & Östman, A. (2024) · Upsala Journal of Medical Sciences · doi:10.48101/ujms.v129.10710 · Cited by 38
Huang, Z., Chen, J., Zhu, T., Li, J., Ng, H. Y., Zhou, Y., Gu, X., Xu, S., & Jia, R. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02533-1 · Cited by 49
Tsou, L. K., Huang, Y., Song, J., Ke, Y., Huang, J., & Shia, K. (2017) · Medicinal Research Reviews · doi:10.1002/med.21464 · Cited by 38
Li, B., Zeng, Y. C., Reeves, P. M., Ran, C., Liu, Q., Qu, X., Liang, Y., Liu, Z., Yuan, J., Leblanc, P. R., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0530 · Cited by 38
Burke, B. P., Miranda, C. S., Lee, R. E., Renard, I., Nigam, S., Clemente, G. S., D’huys, T., Ruest, T., Domarkas, J., Thompson, J. A., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.218008 · Cited by 38
Mechanisms of Resistance to Checkpoint Blockade Therapy
Shi, H., Lan, J., & Yang, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_5 · Cited by 37
Zhou, C., Fan, N., Liu, F., Fang, N., Plum, P. S., Thieme, R., Gockel, I., Gromnitza, S., Hillmer, A. M., Chon, S., et al. (2020) · Cells · doi:10.3390/cells9061481 · Cited by 38
Li, Y., Zhao, Z., Lin, C., Liu, Y., Staveley-O’Carroll, K. F., Li, G., & Cheng, K. (2020) · Theranostics · doi:10.7150/thno.53102 · Cited by 38
Remodeling of Stromal Cells and Immune Landscape in Microenvironment During Tumor Progression
Arora, L., & Pal, D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.596798 · Cited by 39
CXCL12 in Pancreatic Cancer: Its Function and Potential as a Therapeutic Drug Target
Malik, S., Westcott, J. M., Brekken, R. A., & Burrows, F. J. (2021) · Cancers · doi:10.3390/cancers14010086 · Cited by 40
Physiology of chemokines in the cancer microenvironment
Drouillard, D., Craig, B. T., & Dwinell, M. B. (2022) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00151.2022 · Cited by 38
Wong, P. F., Gall, M. G., Bachovchin, W. W., McCaughan, G. W., Keane, F. M., & Gorrell, M. D. (2015) · Peptides · doi:10.1016/j.peptides.2015.11.004 · Cited by 38
Murphy, K. J., Chambers, C. R., Herrmann, D., Timpson, P., & Pereira, B. (2021) · Cancers · doi:10.3390/cancers13143481 · Cited by 37
Tanaka, H. Y., Nakazawa, T., Enomoto, A., Masamune, A., & Kano, M. R. (2023) · Cancers · doi:10.3390/cancers15030724 · Cited by 42
Animal models for studying tumor microenvironment (TME) and resistance to lymphocytic infiltration
Yamaguchi, R., & Perkins, G. A. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1470722 · Cited by 37
T lymphocytes against solid malignancies: winning ways to defeat tumours
Caruana, I., Simula, L., Locatelli, F., & Campello, S. (2018) · Cell Stress · doi:10.15698/cst2018.07.148 · Cited by 37
Boddu, P. C., Borthakur, G. M., Koneru, M., Huang, X., Naqvi, K., Wierda, W. G., Bose, P., Jabbour, E. J., Estrov, Z. E., Burger, J. A., et al. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00369 · Cited by 37
Ping-Pong—Tumor and Host in Pancreatic Cancer Progression
Mu, W., Wang, Z., & Zöller, M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01359 · Cited by 37
Elsayed, M., & Abdelrahim, M. (2021) · Biomedicines · doi:10.3390/biomedicines9040389 · Cited by 37
Kim, J. H., Lee, S., Kang, S. J., Choi, Y. W., Choi, S. Y., Park, J. Y., & Chang, I. H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168887 · Cited by 37
Sun, L., Ke, M.-L., Wang, X., Yin, M., Wei, J., Xu, L., Tian, X., Wang, F., Zhang, H., Fu, S., et al. (2022) · Molecular Carcinogenesis · doi:10.1002/mc.23445 · Cited by 40
Mostafavi, S., Zalpoor, H., & Hassan, Z. M. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00356-2 · Cited by 41
Drosten, M., Guerra, C. E., & Barbacid, M. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031542 · Cited by 43
Lim, J. U., Lee, E., Lee, S., Cho, H. J., Ahn, D. H., Hwang, Y., Choi, J. Y., Yeo, C. D., Park, C. K., & Kim, S. J. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-633 · Cited by 36
Goltz, D., Holmes, E. E., Gevensleben, H., Sailer, V., Dietrich, J., Jung, M., Röhler, M., Meller, S., Ellinger, J., Kristiansen, G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10786 · Cited by 36
Pitarresi, J. R., Liu, X., Sharma, S. M., Cuitiño, M. C., Kladney, R. D., Mace, T. A., Donohue, S., Nayak, S. G., Qu, C., Lee, J., et al. (2016) · Neoplasia · doi:10.1016/j.neo.2016.07.006 · Cited by 36
Immune-Suppressing Cellular Elements of the Tumor Microenvironment
Fearon, D. T. (2016) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-050216-034359 · Cited by 37
Self-citationSEOM Clinical Guideline for the treatment of pancreatic cancer (2016)
Vera, R., Dotor, E., Feliú, J., González‐Flores, E., Laquente, B., Macarulla, T. M., Martínez, E., Maurel, J., Salgado, M., & Manzano, J. L. (2016) · Clinical & Translational Oncology · doi:10.1007/s12094-016-1586-x · Cited by 36
Cortese, N., Capretti, G. L., Barbagallo, M., Rigamonti, A., Takis, P. G., Castino, G. F., Vignali, D., Maggi, G., Gavazzi, F., Ridolfi, C., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0403 · Cited by 35
Immune checkpoints in targeted-immunotherapy of pancreatic cancer: New hope for clinical development
Kiaie, S. H., Sanaei, M., Heshmati, M., Asadzadeh, Z., Azimi, I., Hadidi, S., Jafari, R., & Baradaran, B. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.12.011 · Cited by 37
Tissues and Tumor Microenvironment (TME) in 3D: Models to Shed Light on Immunosuppression in Cancer
Ho, T., & Msallam, R. (2021) · Cells · doi:10.3390/cells10040831 · Cited by 39
Yang, M., Li, D., Jiang, Z., Li, C., Ji, S., Sun, J. P., Chang, Y., Ruan, S., Wang, Z., Liang, R., et al. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0924 · Cited by 35
Targeting glycans for CAR therapy: The advent of sweet CARs
Raglow, Z., McKenna, M. K., Bonifant, C. L., Wang, W., di Magliano, M. P., Stadlmann, J., Penninger, J. M., Cummings, R. D., Brenner, M. K., & Markovitz, D. M. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.07.006 · Cited by 36
Combinatorial Gli activity directs immune infiltration and tumor growth in pancreatic cancer
Scales, M. K., Velez-Delgado, A., Steele, N. G., Schrader, H. E., Stabnick, A. M., Yan, W., Mercado-Soto, N. M., Nwosu, Z., Johnson, C. N., Zhang, Y.-Q., et al. (2022) · PLoS Genetics · doi:10.1371/journal.pgen.1010315 · Cited by 28
Ma, H., Qiu, Q., Tan, D., Chen, Q., Liu, Y., Chen, B., & Wang, M. (2022) · Biomolecules · doi:10.3390/biom13010062 · Cited by 37
Gu, M., Gao, Y., & Chang, P. (2021) · Cancers · doi:10.3390/cancers13102429 · Cited by 35
Exploiting the STAT3 Nexus in Cancer-Associated Fibroblasts to Improve Cancer Therapy
Allam, A. H., Yakou, M. H., Pang, L., Ernst, M., & Huynh, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.767939 · Cited by 38
Crosstalk between fibroblasts and T cells in immune networks
Lee, B., Lee, S., & Shin, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1103823 · Cited by 39
Minini, M., & Fouassier, L. (2023) · Current Oncology · doi:10.3390/curroncol30040319 · Cited by 38
The role of HIF in angiogenesis, lymphangiogenesis, and tumor microenvironment in urological cancers
Shen, L., Chai, Y., Zheng, X., & Xu, X. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08931-2 · Cited by 36
Current status and future challenges of CAR-T cell therapy for osteosarcoma
Li, S., Zhang, H., & Shang, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1290762 · Cited by 37
The Application of Nanoparticles Targeting Cancer-Associated Fibroblasts
Huang, Q., Ge, Y., He, Y. T., Wu, J., Tong, Y., Shang, H., Liu, X., Ba, X., Xia, D., Peng, E., et al. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s447350 · Cited by 35
Xu, A. M., Haro, M., Walts, A. E., Hu, Y., John, J., Karlan, B. Y., Merchant, A. A., & Oršulić, S. (2024) · Science Advances · doi:10.1126/sciadv.adk8805 · Cited by 40
Transcriptome Landscape of Cancer‐Associated Fibroblasts in Human PDAC
Tao, M., Liu, W., Chen, J., Liu, R., Zou, J., Yu, B., Wang, C., Huang, M., Chen, Q., Zhang, Z., et al. (2025) · Advanced Science · doi:10.1002/advs.202415196 · Cited by 50
Lee, H., & Al‐Ogaili, Z. (2025) · Oncology Reviews · doi:10.3389/or.2025.1617487 · Cited by 40
Bever, K. M., Shin, S. M., Durham, J. N., Qi, H., Hernandez, A., Coyne, E. M., Groß, N., Charmsaz, S., Babu, J. S., Carvajal, D. C. V., et al. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2543614 · Cited by 35
Targeting tumor tolerance: A new hope for pancreatic cancer therapy?
Delitto, D., Wallet, S. M., & Hughes, S. J. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.06.008 · Cited by 37
Chen, C., Hou, J., Yu, S., Li, W., Wang, X., Sun, H., Qin, T., Claret, F. X., Guo, H., & Liu, Z. (2021) · Oncology Letters · doi:10.3892/ol.2021.12674 · Cited by 35
Park, S., Karalis, J. D., Hong, C., Clemenceau, J. R. V., Porembka, M. R., Kim, I.-H., Lee, S. H., Wang, S. C., Cheong, J., & Hwang, T. H. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1897 · Cited by 35
Stouten, I., van Montfoort, N., & Hawinkels, L. J. A. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108707 · Cited by 35
An In Vivo Self‐Assembled Bispecific Nanoblocker for Enhancing Tumor Immunotherapy
Hu, X., Zhang, N., Hou, D., Wang, Z., Wang, M., Yi, L., Song, Z., Liang, J., Li, X., An, H., et al. (2023) · Advanced Materials · doi:10.1002/adma.202303831 · Cited by 34
Lou, M., Iwatsuki, M., Wu, X., Zhang, W., Matsumoto, C., & Baba, H. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-14586-x · Cited by 34
Zhang, X., Zhu, R., Yu, D., Wang, J., Yan, Y., & Xu, K. (2023) · Cell Proliferation · doi:10.1111/cpr.13592 · Cited by 35
Qiao, M., Zhou, F., Liu, X., Jiang, T., Wang, H., Li, X., Zhao, C., Cheng, L., Chen, X., Ren, S., et al. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00471-6 · Cited by 35
Zhang, S., Zhou, C., Zhang, D., Huang, Z., & Zhang, G. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s201121 · Cited by 34
Malchiodi, Z. X., & Weiner, L. M. (2021) · Cancers · doi:10.3390/cancers13030405 · Cited by 34
Contextual cues from cancer cells govern cancer-associated fibroblast heterogeneity
Bota‐Rabassedas, N., Banerjee, P., Niu, Y., Cao, W., Luo, J., Xi, Y., Tan, X., Sheng, K., Ahn, Y., Lee, S., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109009 · Cited by 34
Li, X., Yang, Y., Huang, Q., Deng, Y., Guo, F., Wang, G., & Liu, M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.738373 · Cited by 36
Zhao, Y., Liu, Y., Jia, Y., Wang, X., He, J., Zhen, S., Wang, J., & Liu, L. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04250-4 · Cited by 34
Clinical Strategies Targeting the Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma
Skorupan, N., Domínguez, M. P., Ricci, S. L., & Alewine, C. (2022) · Cancers · doi:10.3390/cancers14174209 · Cited by 35
Self‐Adaptive Nanoregulator to Mitigate Dynamic Immune Evasion of Pancreatic Cancer
Pan, J., Lai, Y., Zhang, S., Zhang, H., Shan, Y., Huang, L., Wang, F., Yu, H., Xu, L., & Xu, Z. (2023) · Advanced Materials · doi:10.1002/adma.202305798 · Cited by 33
Metadata
- Authors
- Feig, C., Jones, J. O., Kraman, M., Wells, R. J. B., Deonarine, A., Chan, D. S., Connell, C. M., Roberts, E. W., Zhao, Q., Caballero, O. L., Teichmann, S. A., Janowitz, T., Jodrell, D. I., Tuveson, D. A., & Fearon, D. T.
- Affiliations
- University of Cambridge (GB)
- MRC Laboratory of Molecular Biology (GB)
- Johns Hopkins University (US)
- Ludwig Collaborative Laboratory, Department of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, MD 21231; and
- European Bioinformatics Institute (GB)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2013-11-25
- Volume
- 110
- Issue
- 50
- Pages
- 20212-20217
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC3864274
- OpenAlex
- W2086834665
- Cited by
- 2,100
- References
- 28
- Citations by year
- 2026: 252 · 2025: 157 · 2024: 226 · 2023: 214 · 2022: 221 · 2021: 244 · 2020: 203 · 2019: 149 · 2018: 125 · 2017: 119 · 2016: 95 · 2015: 63 · 2014: 30
- FWCI
- 33.71
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- Funders
- Wellcome Trust
- Cancer Research UK (15678)
- National Institute for Health and Care Research (CL-2011-14-007)
- Medical Research Council (MC_PC_12012)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
- Keywords
- pancreatic ductal adenocarcinoma, CXCL12, fibroblast activation protein, cancer-associated fibroblasts, PD-L1 blockade, CTLA-4 blockade, tumor immune evasion, tumor stroma, CXCR4 inhibition, AMD3100, CD8+ T cells, chemokine signaling, immunotherapy resistance
- MeSH terms
- Cyclams, Fibroblast Activation Protein Alpha, Analysis of Variance, Animals, Base Sequence, Benzylamines, Fibroblasts, Flow Cytometry, Fluorescent Antibody Technique, Heterocyclic Compounds, Immunohistochemistry, Immunotherapy, Membrane Proteins, Molecular Sequence Data, Pancreatic Neoplasms, Endopeptidases, Serine Endopeptidases, Sequence Analysis, RNA, Gelatinases, Tumor Escape, Carcinoma, Pancreatic Ductal, Mice, Chemokine CXCL12, Enzyme-Linked Immunospot Assay
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
